KLRG1, Another Opportunity for a Breakthrough in MTCL

Gaurav Varma; Catherine S Diefenbach

doi:10.1158/1078-0432.CCR-24-0374

KLRG1, Another Opportunity for a Breakthrough in MTCL

Clin Cancer Res. 2024 Jun 3;30(11):2300-2302. doi: 10.1158/1078-0432.CCR-24-0374.

Authors

Gaurav Varma^{1

2}, Catherine S Diefenbach^{1

2}

Affiliations

¹ Division of Hematology and Medical Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, New York.
² Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York.

PMID: 38568191
DOI: 10.1158/1078-0432.CCR-24-0374

Abstract

Outcomes in mature T-cell lymphomas remain poor, with previous attempts at developing mAbs compromised by limited efficacy and significant immunocompromise. Anti-killer cell lectin-like receptor G1 mAbs may have greater selectivity and specificity for malignant T cells and avoid the toxicity concerns with previous agents. See related article by Assatova et al., p. 2514.

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use
Humans
Lectins, C-Type* / antagonists & inhibitors
Lectins, C-Type* / immunology
Lectins, C-Type* / metabolism
Lymphoma, T-Cell / drug therapy
Lymphoma, T-Cell / pathology
Receptors, Immunologic / antagonists & inhibitors
Receptors, Immunologic / immunology
Receptors, Immunologic / metabolism

Substances

Lectins, C-Type
Receptors, Immunologic
Antibodies, Monoclonal